Bucladesine sodium  (Synonyms: Dibutyryl cAMP sodium salt; DBcAMP sodium salt)

Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing^[1][2][3][4].

Both choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) mRNA increased approximately fourfold after treatment of PC12 cells with Bucladesine (dibutyryl cyclic AMP; dbcAMP). ChAT and PKA activity are also increased by Bucladesine^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Intrahippocampal infusion of Bucladesine into the CA1 region (male Albino-Wistar rats) can cause an improvement in spatial memory in maze task. Bilateral infusion of 10 μM and 100 μM Bucladesine leads to a significant reduction in escape latency and travel distance (showing an improvement in spatial memory). Bucladesine via activation of PKA and induction of cAMP/PKA pathway improved spatial memory retention^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

491.37

Solid

C₁₈H₂₃N₅NaO₈P

16980-89-5

O=C(CCC)O[C@H]1[C@H](N2C(N=CN=C3NC(CCC)=O)=C3N=C2)O[C@@](CO4)([H])[C@@]1([H])OP4(O[Na])=O

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Sharifzadeh, M., et al., Post-training intrahippocampal infusion of nicotine-bucladesine combination causes a synergistic enhancement effect on spatial memory retention in rats. Eur J Pharmacol, 2007. 562(3): p. 212-20.  [Content Brief]

  [2]. Mafune, E., M. Takahashi, and N. Takasugi, Effect of vehicles on percutaneous absorption of bucladesine (dibutyryl cyclic AMP) in normal and damaged rat skin. Biol Pharm Bull, 1995. 18(11): p. 1539-43.  [Content Brief]

  [3]. Rundfeldt, C., et al., The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res, 2012.  [Content Brief]

  [4]. Salehi F, et al. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain. Fundam Clin Pharmacol. 2017 Aug;31(4):411-419.  [Content Brief]

  [5]. Shimojo M, et al. The cholinergic gene locus is coordinately regulated by protein kinase A II in PC12 cells. J Neurochem. 1998 Sep;71(3):1118-26.  [Content Brief]